Kirke Weaver - 31 Mar 2024 Form 4 Insider Report for Organon & Co. (OGN)

Role
Gen. Counsel & Corp. Secy.
Signature
/s/ Tarnetta V. Jones, as Attorney-in-Fact for Kirke Weaver
Issuer symbol
OGN
Transactions as of
31 Mar 2024
Net transactions value
-$72,982
Form type
4
Filing time
03 Apr 2024, 18:40:43 UTC
Previous filing
02 Apr 2024
Next filing
07 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OGN Common Stock Options Exercise $0 +4,294 +23% $0.000000 22,825 31 Mar 2024 Direct
transaction OGN Common Stock Tax liability $23,011 -1,224 -5.4% $18.80 21,601 31 Mar 2024 Direct
transaction OGN Common Stock Options Exercise $0 +6,200 +29% $0.000000 27,801 31 Mar 2024 Direct
transaction OGN Common Stock Tax liability $33,220 -1,767 -6.4% $18.80 26,034 31 Mar 2024 Direct
transaction OGN Common Stock Options Exercise $0 +3,125 +12% $0.000000 29,159 31 Mar 2024 Direct
transaction OGN Common Stock Tax liability $16,751 -891 -3.1% $18.80 28,268 31 Mar 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OGN Restricted Stock Units Options Exercise $0 -4,294 -50% $0.000000 4,294 31 Mar 2024 Common Stock 4,294 Direct F1, F2
transaction OGN Restricted Stock Units Options Exercise $0 -3,125 -50% $0.000000 3,125 31 Mar 2024 Common Stock 3,125 Direct F1, F2, F3
transaction OGN Restricted Stock Units Options Exercise $0 -6,200 -33% $0.000000 12,400 31 Mar 2024 Common Stock 6,200 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit converts into one share of Organon & Co. ("Organon") common stock.
F2 The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025.
F3 The Reporting Person was granted RSUs on November 7, 2022, which represent a contingent right to receive one share of Organon common stock for each RSU. On each of March 31, 2023, and March 31, 2024, one-third of the RSUs vested, with the remaining RSUs to vest on March 31, 2025.
F4 The Reporting Person was granted RSUs on March 31, 2023. On March 31, 2024, one-third of the RSUs vested with the remaining RSUs to vest in two equal installments on March 31, 2025 and March 31, 2026.